Efficacy and Safety of Fremanezumab for Migraine Prophylaxis in Patients With at Least Three Previous Preventive Failures: Prospective, Multicenter, Real-World Data From a Greek Registry

The study assessed the efficacy and safety of fremanezumab for migraine prophylaxis in 204 patients who had failed at least three previous preventive treatments. The results showed that fremanezumab was effective in reducing monthly headache days by at least 50% in 83.5% of high-frequency episodic migraine (HFEM) cases and 62.6% of chronic migraine (CM) patients. Additionally, there was a clinically meaningful improvement in migraine-related disability and quality of life. Mild adverse events were reported in 36 cases, including pain, rash, pruritus, flu-like symptoms, and hair loss. The study provided real-world data supporting the favorable benefit/risk profile of fremanezumab for migraine prophylaxis.